Premium
Treatment retention, drug‐use outcomes improved with injectable form of naltrexone
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30389
Subject(s) - naltrexone , medicine , opioid , drug , randomized controlled trial , anesthesia , pharmacology , receptor
The first randomized controlled trial to compare the extended‐release injectable formulation of naltrexone to the oral version for patients with opioid dependence has found greater treatment retention and fewer opioid‐positive drug tests in patients receiving injectable naltrexone. The challenge associated with completing naltrexone induction in patients, who must be opioid‐free for 7 to 10 days before receiving the medication, contributed to a high rate of screen failure in the study, the researchers reported. Study results were published online Oct. 19 in the American Journal of Psychiatry .